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Beta irradiation with 106Ru applicator is
one of the methods of treatment of the tumours
located in eye.
Method
In this method we give a dose of 60 Gy to
the tumour top. The tumour top is located between
2 and 10 mm from eye surface and it is defined as
the border of cancer infiltration. We use echogram
to border localisation. From the source certificate
we know that the dose rate is charged with a 30%
determination error. We increased the calculated
dose considering the error value so that at least
60 Gy dose to the tumour top was delivered.
The critical dose for the sclera is 1500 Gy
and for the lens 15 Gy respectively. We calculated
the maximal dose by the same procedure as the
minimal dose through modifying dose rate by
certificate error. We calculated doses in the sclera
in three places: on the sclera's surface, in the
middle of it (about 0.6 mm depth) and on the
sclera's bottom edge which is the base of the
tumour (about 1.2 mm depth).
Results
Nineteen patients were treated. In all
cases the tumour top received at least 60 Gy. In 4
cases it was impossible to deliver a sufficient dose
(minimum 60 Gy) at the tumour top without
exceeding 1500 Gy in the sclera. It was because
of the tumour size was too large (more than 8
mm). In these cases, there was a probability of
exceeding 1500 Gy on the sclera's surface when
we took the maximal dose rate option. In 4 cases
the dose in the lens exceeded a critical dose but
we have got the medical agreement to do that.
The important thing is to check the tumour
size because the applicator should cover the cancer.
This method of treatment time calculation
is fast and easy. We have written the computer
program for that procedure which reduced the
time of calculation and preparation of the protocol
up to a few minutes.
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Treatment results in glioblastoma
multiforme, irrespective of the management, are
poor. Median survival in patients managed with
surgery alone is 4 months and in those treated
with surgery and adjuvant radiotherpy -9 months.
Twenty eight patients with glioblastoma
multiforme were treated at the Department of
Oncology and Radiotherapy, Medical University
of Gdansk between 1991 to 1995. There were
females and 20 males and the median age was
58 years (range 18 to 75 years). In 22 cases
(78%) diagnosis was confirmed by histology, and
in the remaining six cases biopsy was not taken
due to the deep localization of the tumour;
in all these patients diagnosis was based on CT
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imaging. All patients were irradiated with cobalt
unit and received conventional radiotherapy, 5
days a week, 1.8 Gy per fraction. The first part of
treatment included whole brain irradiation (40 Gy)
delivered through lateral parallel opposed fields.
Thereafter in all instances a brain CT was done
and in case of regression or stabilisation (23 pts),
a boost dose of 15-22 Gy with reduced portals
was delivered. Total dose delivered to the tumor
bed was 55-62 Gy. Radiotherapy tolerance was
satisfactory and there were no serious
complications and interruptions of treatment.
Median local recurrence-free survival
was 5.3 months, and a median survival - 9.9
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months (range, 1.6 to 31.2 months). There was
no correlation between survival and radiotherapy
dose, .sex, pretreatment WHO performance
status and tumor localization.
Our results confirm poor prognosis in
glioblastoma multiforme. New more effective
therapeutic approaches are sorely needed in this
tumour.
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The p53 is transcriptional factor that
enhances the rate of transcription of six or
seven known genes which play important role in
cell cycle regulation. The human p53 protein
contains 393 amino acids and has been divided
structurally and functionally into four domains.
The p53 gene and its protein product have been
studied since it became clear that slightly more
than 50% of human cancers contain mutations
in this gene. A study of mutational spectrum at
the p53 gene are localized predominantly in the
DNA-binding domain of the protein (exons 4-9).
The nature of this changes is most commonly a
missense mutation in one allele followed by a
reduction to homozygosity, producing a faulty
protein. Deletions or chain termination mutations
are more rarely.
Mutations in p53· gene have been also
found in breast cancer in 30-40% of cases. Kind
of these mutations suggest that enviromental
mutagens may play important role in arising of
this type of canceLlt is observed that in West
Poland breast cancer occures more frequently
then in other areas of the country; the highest
numbers of cases are found in GreatPoland still
now for unknown reasons. In this work 48 cases
of breast cancer were studied. 12 different
mutations in p53 were found. This mutations
were then compared with datebase catalogs
containing mutations in p53. Only 3 from 12
found mutations are the same as reported in
datebase. Nine of them were not observed
before what may suggest that specific
mutational spectrum in patients with breast
cancer from GreatPoland exists. Futher studies
involving greater number of cases are needed to
confirm this observation. .
IS ACUTE MUCOSITIS DOSE LIMITING FOR ALTERED FRACTIONATED RADIOTHERAPY?
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There is now a substantial number of studies
on radiotherapy for head and neck cancer using
altered fractionation schedules.
Accumulated dose/week (AD) vs incidence
and severity of acute mucositis
In conventional radiotherapy given in 1.6-2.0
Gy fractions up to total dose of about 70 Gy,
confluent mucositis (CM) is generally reached at
day 22. The threshold for the CM appears to be
around 20 Gy and the CM usually develops
about 9 days after delivering that dose.
However, some studies suggest that the onset
of CM may depend on accumulated dose/week
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and the larger AD is the sooner CM is reached.AII
these observations suggest that the intensity of
acute epithelial reactions, and likely other H-type-
like tissues reflects the balance between the rate
of cell killing by irradiation and the rate of
regeneration of surviving stem cells. Once a
critical level of survival cells has been attained, a
certain type of clinical damage will develop at a
rate only determined by the cellular kinetics of the
tissue. When a peak in the CM is reached, further
stem cell killing can not produce an increase in
intensity of acute reactions, but could be manifest
as prolonged time to heal the reactions.
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